Paul D. Smith

发表

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

B. Taylor, N. Hayward, C. Pratilas, 2010, Cancer research.

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

J. Roth, C. Chresta, Paul D. Smith, 2010, PloS one.

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Li Wang, John D. Minna, Lin Ji, 2009, Cancer biology & therapy.

New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome.

S. Ross, P. Eyers, Paul D. Smith, 2018, Cancer research.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Lucio Crinò, Carlos Barrios, Johan Vansteenkiste, 2013, The Lancet. Oncology.

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Paul D. Martin, Mark Cockerill, Paul D. Smith, 2007, Molecular Cancer Therapeutics.

p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

J. Peto, B. Gusterson, Paul D. Smith, 1998, Oncogene.

Senior Associate Editor

Kwok Wa Leung, S. Hay, P. Maagt, 2009 .

Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

Paul D. Smith, E. Kilgour, Elaine Kilgour, 2012 .

Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions

B. Gusterson, Paul D. Smith, T. Crook, 1999, Oncogene.

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

N. Karp, D. Nguyen, A. Windhorst, 2020, Clinical Cancer Research.

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

Shannon K. Boi, J. Banchereau, S. Barry, 2020, Nature Immunology.

Signal-Regulated Kinase and Raf Proteins Negative Feedback Pathways between Extracellular BRAF V 600 E Disrupts AZD 6244-Induced Abrogation of Updated

S. Thibodeau, Liang Wang, Paul D. Smith, 2008 .

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

Paul D. Smith, N. Ueno, K. Dalby, 2015, Molecular Cancer Therapeutics.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal of Immunotherapy for Cancer.

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

P. Jänne, A. Shaw, L. Crinò, 2012 .

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Paul D. Smith, M. Leach, H. Parkes, 2017, Cancer research.

MCT 1 inhibitor AZD 3965 increases mitochondrial metabolism , facilitating combination therapy and non-invasive magnetic resonance spectroscopy

Paul D. Smith, M. Leach, H. Parkes, 2017 .

Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

B. Telfer, Paul D. Smith, I. Stratford, 2014, Molecular Cancer Therapeutics.

Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

B. Telfer, Paul D. Smith, I. Stratford, 2014, Molecular Cancer Therapeutics.

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Paul D. Smith, R. Wilkinson, B. Barlaam, 2010, Clinical Cancer Research.

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.

Paul D. Smith, Michal Bista, D. Hargreaves, 2021, Journal of medicinal chemistry.

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

K. Politi, W. Lockwood, Paul D. Smith, 2020, Cancer Research.

Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID

A. Bornot, Paul D. Smith, D. Gianni, 2020, SLAS discovery : advancing life sciences R & D.

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Paul D. Smith, B. Cho, Matthew J. Martin, 2020, Molecular Cancer Therapeutics.

Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.

P. Jänne, A. Kohlmann, L. Crinò, 2016 .

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

J. Dry, Paul D. Smith, S. Guichard, 2011, Biochemical Society transactions.

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

M. Ranson, J. Schellens, F. André, 2013 .

Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

M. Ranson, J. Schellens, F. André, 2013 .

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

J. Barrett, F. André, Paul D. Smith, 2014 .

Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance

J. Houseley, S. Cook, Paul D. Smith, 2022, NAR cancer.

Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)

Paul D. Smith, A. Logié, S. Critchlow, 2012 .

Alleles of the rat T-cell receptor β chain gene complex

G. Gutman, Paul D. Smith, E. Blankenhorn, 2004, Immunogenetics.

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

D. Nguyen, K. Politi, Paul D. Smith, 2022, Nature communications.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal for immunotherapy of cancer.

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

K. Politi, W. Lockwood, Paul D. Smith, 2020, Cancer Research.

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

S. Cook, J. Dry, Paul D. Smith, 2019, Nature Communications.

Challenges and Opportunities in Cancer Drug Resistance.

Paul D. Smith, S. Fawell, V. Flemington, 2020, Chemical reviews.

Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.

Anthony D. Keefe, E. Hennessy, A. Keefe, 2021, Journal of medicinal chemistry.

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

R. Dummer, P. Nuciforo, Paul D. Smith, 2011, Pigment cell & melanoma research.

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

S. Cook, Paul D. Smith, C. Caunt, 2015, Nature Reviews Cancer.

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity

S. Barry, Paul D. Smith, R. Wilkinson, 2019, Oncoimmunology.

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

P. Edwards, S. Cook, J. Dry, 2011, Science Signaling.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

P. Jänne, A. Kohlmann, L. Crinò, 2017, JAMA.

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

J. Barrett, J. Dry, D. Hodgson, 2016, Clinical Cancer Research.

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Kakajan Komurov, Gordon B Mills, Prahlad T. Ram, 2014, Cancer research.

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Prahlad T. Ram, P. Ram, K. Komurov, 2010, Cancer research.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

Adrian V. Lee, Laura M. Heiser, P. Spellman, 2014, Breast Cancer Research.

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Edward S. Kim, X. Wang, I. Wistuba, 2013, Clinical Cancer Research.

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

S. Cook, Paul D. Smith, S. Guichard, 2014, Journal of Cell Science.

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Paul D. Smith, C. Dive, F. Blackhall, 2013, Clinical Cancer Research.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

S. Barry, Paul D. Smith, J. Kendrew, 2016, Cell metabolism.

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

A. Tolcher, D. Gandara, Paul D. Smith, 2014, Clinical Cancer Research.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

G. Daley, C. Paweletz, P. Jänne, 2021, Science Translational Medicine.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

D. Adams, J. Saez-Rodriguez, R. McIntyre, 2019, Nature Communications.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

H. Huynh, K. Soo, H. Koong, 2010, Journal of hepatology.

Inhibition of MEK confers hypersensitivity to X‐radiation in the context of BRAF mutation in a model of childhood astrocytoma

P. Houghton, Paul D. Smith, X. Mo, 2015, Pediatric blood & cancer.

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

S. Barry, Paul D. Smith, E. Harrington, 2014, Molecular Cancer Therapeutics.

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

D. Largaespada, O. Delpuech, Paul D. Smith, 2021, Neuro-oncology advances.

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts

B. Telfer, Paul D. Smith, I. Stratford, 2009, Clinical Cancer Research.

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

Chunrong Yu, S. Thibodeau, Liang Wang, 2008, Cancer research.

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

J. Barrett, J. Downward, Paul D. Smith, 2021, Nature Communications.

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

S. Cook, Paul D. Smith, K. Balmanno, 2012, Biochemical Society transactions.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

M. Firth, Paul D. Smith, Kate F. Byth, 2017, Oncotarget.

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Barry R Davies, Yi-long Wu, S. Runswick, 2012, Cancer research.

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Kwok-Kin Wong, J. Wolchok, Paul D. Smith, 2019, Cell reports.

DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene

J. Houseley, S. Cook, Paul D. Smith, 2021, bioRxiv.

Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma

Mariko DeWire, Soledad Fernandez, David Capper, 2013, Clinical Cancer Research.

Cancer Therapy : Preclinical Development , Characterization , and Reversal of Acquired Resistance to theMEK 1 Inhibitor Selumetinib ( AZD 6244 ) in an In Vivo Model of Childhood Astrocytoma

P. Houghton, D. Capper, Paul D. Smith, 2013 .

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Paul D. Smith, D. Camidge, R. Agarwal, 2010, Clinical Cancer Research.

Cancer Therapy : Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD 3965 in Small Cell Lung Cancer

Paul D. Smith, C. Dive, F. Blackhall, 2014 .

Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis

I. Wistuba, R. Herbst, R. Komaki, 2012, Clinical Cancer Research.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

J. Barrett, T. French, Paul D. Smith, 2016, PloS one.

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Roman K. Thomas, Paul D. Smith, E. Kilgour, 2012, Clinical Cancer Research.

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

K. Politi, Paul D. Smith, Z. Cooper, 2022, JCI insight.

Cancer Therapy: Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Paul D. Smith, A. White, C. Dive, 2014 .

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

P. Nelson, Patricia D. Castro, M. Ittmann, 2016, Oncotarget.

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

M. Garnett, O. Delpuech, Paul D. Smith, 2020, Molecular Cancer Therapeutics.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

D. Tuveson, Paul D. Smith, V. Corbo, 2019, Clinical Cancer Research.

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

A. Berns, L. Wessels, Paul D. Smith, 2018, Cancer research.

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

O. Delpuech, J. Dry, Paul D. Smith, 2016, Molecular Cancer Therapeutics.

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Paul D. Smith, I. Prior, J. Coulson, 2022, The Biochemical journal.

Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD

Paul D. Smith, O. Vaarala, P. Svanberg, 2019, International journal of chronic obstructive pulmonary disease.

COPD_A_211619 2611..2624

Paul D. Smith, O. Vaarala, P. Svanberg, 2019 .

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

Shannon K. Boi, J. Banchereau, S. Barry, 2020, Nature Immunology.

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis

C. Swanton, Paul D. Smith, M. Bustin, 2020, Nature Communications.

Cancer esearch apeutics , Targets , and Chemical Biology al and Treatment-Induced Activation of AKT Mediates istance to Cell Death by AZD 6244 ( ARRY-142886 ) in R f-Mutant Human Cutaneous Melanoma Cells

K. Komurov, S. Woodman, Paul D. Smith, 2010 .

P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

J. Riess, Paul D. Smith, I. Okamoto, 2021 .

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

N. Rosen, Paul D. Smith, Xiaoxiao Hu, 2020, Molecular oncology.

MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands

D. Citrin, Paul D. Smith, E. Chung, 2013, International journal of oncology.

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

J. Riess, Paul D. Smith, P. Jewsbury, 2019, Journal of Thoracic Oncology.

Selumetinib-based therapy in uveal melanoma patient-derived xenografts

G. Massonnet, S. Roman-Roman, Paul D. Smith, 2018, Oncotarget.

265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis

Paul D. Smith, B. Davies, A. Logié, 2008 .

Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.

E. Hennessy, Nichola L. Davies, A. Doherty, 2021, Journal of medicinal chemistry.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

D. Adams, J. Sáez-Rodríguez, R. McIntyre, 2019, Nature Communications.

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

H. Ditzel, C. Tornador, G. Fabbri, 2023, Molecular Cancer.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

P. Jänne, A. Shaw, L. Crinò, 2015, British Journal of Cancer.

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Paul D. Smith, D. Hargreaves, Matthew J. Martin, 2019, Cancer Chemistry.

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

A. Ryan, P. Elvin, Paul D. Smith, 2010 .

EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.

E. Dreher, Paul D. Smith, P. D. Smith, 2001, International journal of oncology.